We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PDL BioPharma Inc | NASDAQ:PDLI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.47 | 2.62 | 2.63 | 0 | 01:00:00 |
Delaware
|
|
94-3023969
|
(State or Other Jurisdiction of Incorporation)
|
|
(I.R.S. Employer Identification No.)
|
•
|
The audited special purpose financial statements, which comprise a statement of assets acquired as of December 31, 2015, the related statement of revenues and direct expenses for the year ended December 31, 2015 and the notes thereto, which are filed as Exhibit 99.1.
|
•
|
The unaudited special purpose interim financial statements, which comprise a statement of assets acquired as of June 30, 2016, related statement of revenues and direct expenses for the six months ended June 30, 2016 and 2015 and the notes thereto, which are filed as Exhibit 99.2.
|
(c)
|
Exhibits.
|
Exhibit No.
|
|
Description
|
23.1
|
|
Consent of PricewaterhouseCoopers AG.
|
|
|
|
99.1
|
|
The audited Special Purpose Financial Statements (Statement of Assets Acquired as of December 31, 2015, Related Statement of Revenues and Direct Expenses for the year ended December 31, 2015 and the Notes thereto).
|
|
|
|
99.2
|
|
The unaudited Special Purpose Interim Financial Statements (Statement of Assets Acquired as of June 30, 2016, Related Statement of Revenues and Direct Expenses for the six months ended June 30, 2016 and 2015 and the Notes thereto).
|
|
|
|
99.3
|
|
Unaudited Pro Forma Condensed Combined Balance Sheet and Statements of Income.
|
PDL BIOPHARMA, INC.
|
||
|
||
|
|
|
By:
|
|
/s/ Peter S. Garcia
|
|
|
Peter S. Garcia
|
|
|
Vice President and Chief Financial Officer
|
Exhibit No.
|
|
Description
|
23.1
|
|
Consent of PricewaterhouseCoopers AG.
|
|
|
|
99.1
|
|
The audited Special Purpose Financial Statements (Statement of Assets Acquired as of December 31, 2015, Related Statement of Revenues and Direct Expenses for the year ended December 31, 2015 and the Notes thereto).
|
|
|
|
99.2
|
|
The unaudited Special Purpose Interim Financial Statements (Statement of Assets Acquired as of June 30, 2016, Related Statement of Revenues and Direct Expenses for the six months ended June 30, 2016 and 2015 and the Notes thereto).
|
|
|
|
99.3
|
|
Unaudited Pro Forma Condensed Combined Balance Sheet and Statements of Income.
|
1 Year PDL BioPharma Chart |
1 Month PDL BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions